wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 554.
1 2 3 4 5 ... 12 Next »

Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS   Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined) and 38% achieved NEDA-4 (NEDA-3 plus no brain shrinkage), further supporting findings from clinic
Medicine/Pharmacology - Life Sciences
24.04.2017
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada Novartis and Amgen to co-commercialize AMG 334
Medicine/Pharmacology - Life Sciences
21.04.2017
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.
Medicine/Pharmacology - Life Sciences
19.04.2017
Action Required: Invasive Fungus Is Killing European Salamanders
The situation is alarming: The invasive Asian fungus has recently led to mass mortality of fire salamanders in the Netherlands, Belgium and Germany.
Medicine/Pharmacology - Life Sciences
19.04.2017
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis
Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS? (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and
Medicine/Pharmacology - Life Sciences
18.04.2017
FDA grants Roche’s TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer
FDA grants Roche's TECENTRIQ (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder
Medicine/Pharmacology - Life Sciences
18.04.2017
Chaining up diarrhoea pathogens
Chaining up diarrhoea pathogens
Researchers have clarified how vaccinations can combat bacterial intestinal diseases: vaccine-induced antibodies in the intestine chain up pathogens as they grow in the intestine, which prevents disease and surprisingly also hinders the spread of antibiotic resistance. Vaccinations are known to protect against pathogens such as bacteria or viruses.
Medicine/Pharmacology - Life Sciences
18.04.2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)   R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation   Advances in CTL019 result from collaboration with the University of Pennsylvania; regulatory submissions for r/r DLBCL are expected
Medicine/Pharmacology - Life Sciences
18.04.2017
Synthetic Carbohydrates against Autoimmune Diseases
Researchers are developing an innovative approach for the treatment of a rare autoimmune disease of the peripheral nervous system, using a type of molecular sponge consisting of carbohydrates to remove pathogenic antibodies from the bloodstream. Developed to treat anti-MAG neuropathy, the approach also has potential applications for the treatment of other autoimmune diseases.
Life Sciences
11.04.2017
Relocation of Proteins with a New Nanobody Tool
Relocation of Proteins with a New Nanobody Tool
Researchers at the Biozentrum of the University of Basel have developed a new method by which proteins can be transported to a new location in a cell. The novel tool enables scientists to study the function of proteins depending on their position by using nanobodies. The tool can be used for a wide range of proteins and in various areas of developmental biology.
Medicine/Pharmacology - Life Sciences
10.04.2017
Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment Data will be submitted to global
Medicine/Pharmacology - Life Sciences
04.04.2017
Less Fear: how LSD Affects the Brain
Scientists at the University of Basel have shown that LSD reduces activity in the region of the brain related to the handling of negative emotions like fear. The results, published in the scientific journal Translational Psychiatry, could affect the treatment of mental illnesses such as depression or anxiety.
Medicine/Pharmacology - Life Sciences
03.04.2017
Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate in b
Medicine/Pharmacology - Life Sciences
03.04.2017
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
Phase III ALUR study supports the use of Roche's Alecensa for people with advanced ALK-positive lung cancer Results from the global, phase III ALUR trial showed that Alecensa significantly improved progression-free survival (PFS) in people with advanced ALK-positive non-small cell lung cancer (NSCLC) who had progressed following platinum-based chemotherapy and crizotinib, compared with chemotherapy Roche today announced that the phase III ALUR s
Medicine/Pharmacology - Life Sciences
29.03.2017
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T'cells Novartis made an early commitment to the emer
Medicine/Pharmacology - Life Sciences
29.03.2017
FDA approves Roche‘s OCREVUS’ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
FDA approves Roche‘s OCREVUS' (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis First and only approved disease-modifying therapy for primary progressive form of m
Environment/Sustainable Development - Life Sciences
20.03.2017
ACE completes its voyage around Antarctica
The Antarctic Circumnavigation Expedition (ACE) reached Cape Town on Sunday, 19 March, completing its three-month voyage around the great white continent. But the scientific adventure has only just begun: it's now time to analyze all the data that was collected. This will improve our understanding of the effects of global warming on the Southern Ocean and the broader implications for our planet as a whole.
Life Sciences - Medicine/Pharmacology
17.03.2017
Cut the long story short - and stitch it back together
Cut the long story short - and stitch it back together
Media releases, information for representatives of the media Media Relations (E) A species of unicellular ciliate has found a special trick to make use of the cellular machinery in seemingly impossible ways.
Life Sciences - Environment/Sustainable Development
14.03.2017
Spiders Eat 400-800 Million Tons of Prey Every Year
Spiders Eat 400-800 Million Tons of Prey Every Year
It has long been suspected that spiders are one of the most important groups of predators of insects.
Medicine/Pharmacology - Life Sciences
13.03.2017
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Approved based on a first-line P
Medicine/Pharmacology - Life Sciences
13.03.2017
Joint Efforts Towards Treating Paralysis
EPFL scientists Stéphanie Lacour and Grégoire Courtine report on the status of their research and share their vision about the future of wearable neuroprosthetics at this year's edition of South by South West in Austin, Texas, on March 12 th .
Life Sciences - Physics/Materials Science
10.03.2017
New professors appointed
New professors appointed
The ETH Board appointed three new professors and awarded the title of Professor to five recipients upon application of ETH President Lino Guzzella At its meeting of 8/9 March 2017, the ETH Board appo
Medicine/Pharmacology - Life Sciences
06.03.2017
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira * Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio Holzkirchen, 6 March 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017).
Life Sciences - Chemistry
01.03.2017
Researchers Imitate Molecular Crowding in Cells
Researchers Imitate Molecular Crowding in Cells
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Life Sciences - Medicine/Pharmacology
28.02.2017
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Media releases, information for representatives of the media Media Relations (E) Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bio
Medicine/Pharmacology - Life Sciences
24.02.2017
Novartis receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients with B
Medicine/Pharmacology - Life Sciences
23.02.2017
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.
Medicine/Pharmacology - Life Sciences
18.02.2017
Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Proof of concept study in first line mRCC (a type of kidney cancer) shows that TECENTRIQ and Avastin can be combined with a manageable safety profile Study results also showed encouraging efficacy compared to sunitinib in those people whose disease expressed the PD-L1 (programmed de
Computer Science/Telecom - Life Sciences
17.02.2017
Six-Legged Robots Faster Than Nature-Inspired Gait
Six-Legged Robots Faster Than Nature-Inspired Gait
Researchers at EPFL and UNIL have discovered a faster and more efficient gait, never observed in nature, for six-legged robots walking on flat ground. Bio-inspired gaits - less efficient for robots - are used by real insects since they have adhesive pads to walk in three dimensions. The results provide novel approaches for roboticists and new information to biologists.
Chemistry - Life Sciences
07.02.2017
Tiny organisms with a massive impact
Tiny organisms with a massive impact
Although diatoms are incredibly small, they have a significant impact on the dispersal of nutrients and trace elements in global marine waters. This is the conclusion of a study recently published in the scientific journal - Nature Geoscience '. Diatoms are a very common group of algae found not only in freshwater streams, rivers and lakes, but also in marine waters.
Life Sciences - Social Sciences
06.02.2017
Psychotherapy normalizes the brain in social phobia
Anxiety in social situations is not a rare problem: Around one in ten people are affected by social anxiety disorder during their lifetime. Social anxiety disorder is diagnosed if fears and anxiety in social situations significantly impair everyday life and cause intense suffering. Talking in front of a larger group can be one typical feared situation.
Business/Economics - Life Sciences
31.01.2017
In cold water
In cold water
Martin Ostermaier wanted to break out of the comfort zone of science. Now, instead of pipettes, the biochemist is dealing with investors and patent law.
Medicine/Pharmacology - Life Sciences
31.01.2017
Novartis drug Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC)   Approval addresses unmet need as up
Life Sciences - Business/Economics
30.01.2017
The Attraction Effect: how our Brains Can Be Influenced
The Attraction Effect: how our Brains Can Be Influenced
The decisions we make are influenced by other possibilities that we did not choose. At the same time, the options we missed out on determine our satisfaction with the outcomes of situations we were unable to control. Psychologists from the University of Basel conducted two experiments: first, they studied the decision-making behavior of students and, second, they measured brain activity and satisfaction when a set of possibilities is supplemented with another alternative.
Medicine/Pharmacology - Life Sciences
27.01.2017
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Cellestia Biotech, an EPFL spin-off, can now carry out clinical trials on its new cancer treatment after raising CHF 8 million in seed money.
Life Sciences - Medicine/Pharmacology
26.01.2017
LSD alters perception via serotonin receptors
Humans perceive everyday things and experiences differently and attach different meaning to pieces of music, for instance. In the case of psychiatric disorders, this perception is often altered. For patients suffering from addictions, for instance, drug stimuli are more meaningful than for people without an addiction.
Life Sciences - Medicine/Pharmacology
23.01.2017
Immune Defense Without Collateral Damage
Immune Defense Without Collateral Damage
Researchers from the University of Basel in Switzerland have clarified the role of the enzyme MPO. In fighting infections, this enzyme, which gives pus its greenish color, produces a highly aggressive acid that can kill pathogens without damaging the surrounding tissue. In the human body's fight against bacterial pathogens, white blood cells are in the front line.
Life Sciences - Medicine/Pharmacology
20.01.2017
Cell fate regulation by LIN41: activity determined by binding location
Helge Großhans and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mode of action of the RNA-binding protein and stem cell factor LIN41. In an animal model, they showed that LIN41 silences four specific mRNAs, by two distinct mechanisms. They found that the choice of mechanism is determined by where on the mRNA LIN41 binds.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
16.01.2017
Every Meal Triggers Inflammation
When we eat, we do not just take in nutrients - we also consume a significant quantity of bacteria. The body is faced with the challenge of simultaneously distributing the ingested glucose and fighting these bacteria.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Environment/Sustainable Development - Life Sciences
20.12.2016
University of Zurich to become global center for biodiversity research
University of Zurich to become global center for biodiversity research
Prof. Michael Schaepman, PhD Department of Geography University of Zurich Phone +41 44 635 51 60 E-mail Prof. Bernhard Schmid, PhD Institute of Evolutionary Biology and Environmental Studies
Life Sciences - Administration/Government
20.12.2016
1 2 3 4 5 ... 12 Next »